Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnous GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread

This randomised, double blind, placebo-controlled study sought to determine the survival of Lactobacillus reuteri DSM 17938 and L. rhamnosus GG when ingested as part of a low-fat probiotic spread in 42 healthy human volunteers. Volunteers were randomly assigned to one of three treatment groups provided with placebo spread (n=13), spread with a target dose of 1 x 109 CFU of L. reuteri DSM 17938 (n=13), or spread with a target dose of 5 x 109 CFU of L. rhamnosus GG (n=16) daily for 3 weeks. A significant increase in bacterial counts for both strains was recorded in faecal samples after 3 weeks of daily consumption of the low-fat probiotic spread.

Conclusion:

Low-fat spread is a suitable carrier for these probiotic strains.

Reference

Dommels YEM, Kemperman RA, Zebregs YEMP, Draaisma RB, Jol A, Wolvers DAW, Vaughan EE, Albers R. (2009) Human gastrointestinal tract survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG after daily consumption of a low fat probiotic spread. Appl Envir Microbiol. 75:6198-62hu04.